Figure 2

G6PD-deficient red cell survival following daily primaquine dosing. G6PD-deficient red cell survival was assessed by ⁵¹Cr labelling and transfusion into G6PD-normal healthy recipients (15 mg/day or 45 mg single dose in Mahidol or Viengchan variants, 30 mg/day Mediterranean variant, and a range of doses in African A- variant). The corresponding haematocrit reductions following continuous dosing (or in the green bar, a single dose) in G6PD-deficient subjects are shown in the inset [17, 21–24, 37].